Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10381171rdf:typepubmed:Citationlld:pubmed
pubmed-article:10381171lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0008169lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0021665lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:10381171lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:10381171pubmed:issue9lld:pubmed
pubmed-article:10381171pubmed:dateCreated1999-9-10lld:pubmed
pubmed-article:10381171pubmed:abstractTextIn this study, we have investigated the ability of insulin-like growth factor I (IGF-I) to inhibit HIV long terminal repeat (LTR)-driven gene expression. Using COS 7 cells cotransfected with tat and an HIV LTR linked to a chloramphenicol acetyltransferase (CAT) reporter, we observed that physiological levels of IGF-I (10(-9) M) significantly inhibited CAT expression in a concentration- and time-dependent manner. IGF-I did not inhibit CAT expression in COS 7 cells transfected with pSVCAT, and did not affect CAT expression in the absence of cotransfection with tat. Transfection of HIV-1 proviral DNA into COS 7 cells +/- IGF-I resulted in a significant decrease (p < 0.05) in infectious virion production. Both IGF-I and Ro24-7429 inhibited LTR-driven CAT expression, while TNF-alpha-enhanced CAT expression was not affected by IGF-I. On the other hand, a plasmid encoding parathyroid hormone-related peptide exhibited dramatic additivity of inhibition of CAT expression in COS 7 cells. Finally, we show that in Jurkat or U937 cells cotransfected with HIVLTRCAT/tat, IGF-I significantly inhibited CAT expression. Further, interleukin 4 showed in U937 cells inhibition of CAT expression that was not additive to IGF-I induced inhibition. Our data demonstrate that IGF-I can specifically inhibit HIVLTRCAT expression. This inhibition may occur at the level of the tat/TAR interaction. Finally, this IGF-I effect is seen in target cell lines and similar paths of inhibition may be involved in the various cell types employed.lld:pubmed
pubmed-article:10381171pubmed:languageenglld:pubmed
pubmed-article:10381171pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:citationSubsetIMlld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10381171pubmed:statusMEDLINElld:pubmed
pubmed-article:10381171pubmed:monthJunlld:pubmed
pubmed-article:10381171pubmed:issn0889-2229lld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:GerminarioR...lld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:WainbergM AMAlld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:Colby-Germina...lld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:MaiHHlld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:KleimanLLlld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:DavisonKKlld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:FaussDDlld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:ChandonMMlld:pubmed
pubmed-article:10381171pubmed:authorpubmed-author:AcelAAlld:pubmed
pubmed-article:10381171pubmed:issnTypePrintlld:pubmed
pubmed-article:10381171pubmed:day10lld:pubmed
pubmed-article:10381171pubmed:volume15lld:pubmed
pubmed-article:10381171pubmed:ownerNLMlld:pubmed
pubmed-article:10381171pubmed:authorsCompleteYlld:pubmed
pubmed-article:10381171pubmed:pagination829-36lld:pubmed
pubmed-article:10381171pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:meshHeadingpubmed-meshheading:10381171...lld:pubmed
pubmed-article:10381171pubmed:year1999lld:pubmed
pubmed-article:10381171pubmed:articleTitleEffect of insulin-like growth factor I on HIV type 1 long terminal repeat-driven chloramphenicol acetyltransferase expression.lld:pubmed
pubmed-article:10381171pubmed:affiliationLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.lld:pubmed
pubmed-article:10381171pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10381171pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3479entrezgene:pubmedpubmed-article:10381171lld:entrezgene
entrez-gene:155871entrezgene:pubmedpubmed-article:10381171lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:10381171lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:10381171lld:entrezgene